SHR-A1811, a novel anti-HER2 antibody–drug conjugate with optimal drug-to-antibody ratio, efficient tumor killing potency, and favorable safety profiles

Name: SHR-A1811, a novel anti-HER2 antibody–drug conjugate with optimal drug-to-antibody ratio, efficient tumor killing potency, and favorable safety profiles
Creator: Hengrui
Published: 2024-11-19T00:00:00+08:00

科学数据银行2024-11-27 更新2026-04-23 收录

HER2靶向ADC药物研发

抗肿瘤药物效力与安全性评估

数据链接：

https://www.scidb.cn/detail?dataSetId=559fad0da410477b9341496f42cb6bcb 数据链接链接失效反馈

官方服务：

资源简介：

Data for SHR-A1811, a novel anti-HER2 antibody–drug conjugate with optimal drug-to-antibody ratio, efficient tumor killing potency, and favorable safety profiles.

提供机构：

Hengrui

创建时间：

2024-11-19

SHR-A1811, a novel anti-HER2 antibody–drug conjugate with optimal drug-to-antibody ratio, efficient tumor killing potency, and favorable safety profiles

资源简介：

相关数据集